| Literature DB >> 32411128 |
Michael F Criscitiello1,2, Igor Kraev3, Lene H Petersen4, Sigrun Lange5.
Abstract
Alligators are crocodilians and among few species that endured the Cretaceous-Paleogene extinction event. With long life spans, low metabolic rates, unusual immunological characteristics, including strong antibacterial and antiviral ability, and cancer resistance, crocodilians may hold information for molecular pathways underlying such physiological traits. Peptidylarginine deiminases (PADs) are a group of calcium-activated enzymes that cause posttranslational protein deimination/citrullination in a range of target proteins contributing to protein moonlighting functions in health and disease. PADs are phylogenetically conserved and are also a key regulator of extracellular vesicle (EV) release, a critical part of cellular communication. As little is known about PAD-mediated mechanisms in reptile immunology, this study was aimed at profiling EVs and protein deimination in Alligator mississippiensis. Alligator plasma EVs were found to be polydispersed in a 50-400-nm size range. Key immune, metabolic, and gene regulatory proteins were identified to be posttranslationally deiminated in plasma and plasma EVs, with some overlapping hits, while some were unique to either plasma or plasma EVs. In whole plasma, 112 target proteins were identified to be deiminated, while 77 proteins were found as deiminated protein hits in plasma EVs, whereof 31 were specific for EVs only, including proteins specific for gene regulatory functions (e.g., histones). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed KEGG pathways specific to deiminated proteins in whole plasma related to adipocytokine signaling, while KEGG pathways of deiminated proteins specific to EVs included ribosome, biosynthesis of amino acids, and glycolysis/gluconeogenesis pathways as well as core histones. This highlights roles for EV-mediated export of deiminated protein cargo with roles in metabolism and gene regulation, also related to cancer. The identification of posttranslational deimination and EV-mediated communication in alligator plasma revealed here contributes to current understanding of protein moonlighting functions and EV-mediated communication in these ancient reptiles, providing novel insight into their unusual immune systems and physiological traits. In addition, our findings may shed light on pathways underlying cancer resistance, antibacterial and antiviral resistance, with translatable value to human pathologies.Entities:
Keywords: American alligator (Alligator mississippiensis); antimicrobial/antiviral; extracellular vesicles; immunity; metabolism; peptidylarginine deiminases; protein deimination/citrullination
Mesh:
Substances:
Year: 2020 PMID: 32411128 PMCID: PMC7198796 DOI: 10.3389/fimmu.2020.00651
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Extracellular vesicle profiling in alligator plasma. (A) Nanoparticle tracking analysis shows a size distribution of plasma extracellular vesicles (EVs) from Alligator mississippiensis in the size range of mainly 50–400 nm, albeit with some individual variation in EV profiles within these size ranges and peaks at smaller (30 nm) and larger (500 nm) sizes, with main peaks at ~50, 100, 200, 300, and 400 nm. (B) Western blotting analysis confirms that alligator EVs are positive for the phylogenetically conserved EV-specific markers CD63 and Flot-1. (C) Transmission electron microscopy (TEM) analysis of alligator plasma-derived EVs shows typical EV morphology; scale bar is 100 nm in all figures. (D) EV yield in alligator plasma (n = 3). (E) EV modal size in alligator plasma (n = 3).
Figure 2Peptidylarginine deiminases (PADs) and deiminated proteins in alligator plasma and plasma extracellular vesicles (EVs). (A) PAD positive bands were identified at the expected size range of approximately 70–75 kDa using the antihuman PAD2-, PAD3-, and PAD4-specific antibodies in alligator plasma. (B) Plasma EVs show positive for PAD2 and for PAD3 at lower levels but negative for PAD4 (at expected 70–75 kDa size range), using antihuman PAD isozyme-specific antibodies against PAD2, PAD3, and PAD4, respectively. (C) Total deiminated proteins were identified in alligator plasma using the pan-deimination-specific F95 antibody. (D) Total deiminated proteins were identified in alligator plasma EVs using the pan-deimination-specific F95 antibody. (E,F) F95-enriched IP fraction from alligator plasma (E) and plasma EVs (F), shown by silver staining. (G) Deiminated histone H3 (citH3) is detected in alligator plasma. The F95-enriched IP fraction derived from a pool of three individual alligator plasma and a pool of plasma EVs (n = 3) is shown, respectively.
Deiminated proteins in plasma of alligator (Alligator mississippiensis), as identified by F95 enrichment and liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis.
| Uncharacterized protein (complement C3) | A0A151NL74_ALLMI | 84 | 5,545 |
| Uncharacterized protein (venom factor) | A0A151NM44_ALLMI | 64 | 4,001 |
| Uncharacterized protein | A0A151NFJ9_ALLMI | 55 | 3,599 |
| Uncharacterized protein | A0A151MJS8_ALLMI | 55 | 3,527 |
| Uncharacterized protein | A0A151NDR9_ALLMI | 51 | 3,205 |
| Serum albumin | A0A151N5S7_ALLMI | 45 | 2,909 |
| Fibrinogen beta chain | A0A151N5S7_ALLMI | 37 | 2,603 |
| Uncharacterized protein | A0A151N583_ALLMI | 38 | 2,432 |
| Fibrinogen gamma chain | A0A151PB79_ALLMI | 33 | 2,280 |
| Alpha-2-macroglobulin-like | A0A151NFQ0_ALLMI | 28 | 2,233 |
| Plasminogen | A0A151M2C0_ALLMI | 36 | 2,185 |
| Plasminogen | A0A151M2C2_ALLMI | 36 | 2,184 |
| Uncharacterized protein | A0A151MZ64_ALLMI | 31 | 2,150 |
| Complement receptor type 1-like | A0A151MS72_ALLMI | 27 | 1,798 |
| Uncharacterized protein | A0A151NDR1_ALLMI | 25 | 1,797 |
| Melanotransferrin | A0A151MJZ7_ALLMI | 27 | 1,766 |
| Kininogen-1 | A0A151M678_ALLMI | 24 | 1,693 |
| Hemopexin | A0A151NGB2_ALLMI | 23 | 1,662 |
| Plasma kallikrein isoform B | A0A151PAG7_ALLMI | 26 | 1,627 |
| Complement C5 | A0A151NUM2_ALLMI | 22 | 1,426 |
| Uncharacterized protein | A0A151NLW7_ALLMI | 20 | 1,328 |
| Uncharacterized protein | A0A151MYR7_ALLMI | 19 | 1,304 |
| Uncharacterized protein | A0A151MYS3_ALLMI | 16 | 1,191 |
| Uncharacterized protein | A0A151MJK7_ALLMI | 19 | 1,183 |
| Uncharacterized protein | A0A151NAV0_ALLMI | 19 | 1,181 |
| Fetuin-B isoform B | A0A151M7P5_ALLMI | 20 | 1,164 |
| Complement factor H | A0A151NM72_ALLMI | 17 | 1,054 |
| IgGFc-binding protein-like | A0A151MJC3_ALLMI | 14 | 1,043 |
| Vitamin D-binding protein | A0A151N541_ALLMI | 19 | 998 |
| Carbonic anhydrase 6 | A0A151N4K1_ALLMI | 15 | 920 |
| Uncharacterized protein | A0A151MYV2_ALLMI | 12 | 911 |
| Uncharacterized protein | A0A151P5P7_ALLMI | 15 | 873 |
| CD5 antigen-like | A0A151PHB7_ALLMI | 13 | 867 |
| Antithrombin-III | A0A151MIW1_ALLMI | 13 | 792 |
| Uncharacterized protein | A0A151MYX2_ALLMI | 10 | 752 |
| Uncharacterized protein | A0A151PB91_ALLMI | 9 | 726 |
| Ovoinhibitor | A0A151MEG6_ALLMI | 11 | 625 |
| Coagulation factor XII | A0A151NM16_ALLMI | 8 | 610 |
| Alpha-1-inhibitor 3-like | A0A151M7F0_ALLMI | 11 | 591 |
| T-cell surface glycoprotein CD8 beta chain | A0A151P975_ALLMI | 6 | 567 |
| Hemoglobin subunit alpha-A | A0A151P678_ALLMI | 9 | 538 |
| Uncharacterized protein | A0A151MYQ9_ALLMI | 8 | 514 |
| Ig lambda chain V-1 region | A0A151P8L7_ALLMI | 6 | 500 |
| Uncharacterized protein | A0A151MZ31_ALLMI | 7 | 484 |
| Heparin cofactor 2 isoform B | A0A151MLS1_ALLMI | 9 | 483 |
| Glutathione peroxidase | A0A151MUD9_ALLMI | 8 | 480 |
| Uncharacterized protein | A0A151MYZ1_ALLMI | 6 | 479 |
| Inter-alpha-trypsin inhibitor heavy chain H2 isoform A | A0A151NPL6_ALLMI | 8 | 459 |
| Ficolin-3 | A0A151NG70_ALLMI | 8 | 455 |
| Hemoglobin subunit beta | A0A151PG12_ALLMI | 7 | 450 |
| Ig epsilon chain C region | A0A151MYW1_ALLMI | 7 | 439 |
| Apolipoprotein E | A0A151N3F1_ALLMI | 6 | 430 |
| Complement factor I | A0A151MIQ2_ALLMI | 7 | 424 |
| Fibrinogen C-terminal domain-containing protein | A0A151MF51_ALLMI | 5 | 420 |
| TED_complement domain-containing protein | A0A151N5Z3_ALLMI | 6 | 417 |
| Complement C1q subcomponent subunit B | A0A151MZU2_ALLMI | 6 | 374 |
| Alpha-1-antitrypsin | A0A151P8U9_ALLMI | 6 | 367 |
| Uncharacterized protein | A0A151M7P2_ALLMI | 4 | 351 |
| Coagulation factor XIII B chain | A0A151NCL4_ALLMI | 5 | 333 |
| Alpha-1-antitrypsin | A0A151P8P3_ALLMI | 6 | 322 |
| Alpha-2-antiplasmin | A0A151LY18_ALLMI | 6 | 321 |
| Fructose-bisphosphate aldolase | A0A151MLN4_ALLMI | 4 | 303 |
| Basement membrane-specific heparan sulfate proteoglycan core protein | A0A151MTT0_ALLMI | 5 | 299 |
| Coagulation factor XIII A chain isoform A | A0A151NCL4_ALLMI | 7 | 295 |
| Complement C1q subcomponent subunit C | A0A151N005_ALLMI | 4 | 290 |
| Uncharacterized protein | A0A151MFZ6_ALLMI | 5 | 271 |
| Zinc finger and BTB domain-containing protein 4 | A0A151MYL8_ALLMI | 5 | 265 |
| Complement C1q subcomponent subunit A | A0A151MZN0_ALLMI | 4 | 245 |
| Keratin, type I cytoskeletal 19 | A0A151PC64_ALLMI | 4 | 234 |
| Haptoglobin | A0A151MVG5_ALLMI | 4 | 228 |
| Ig-like domain-containing protein | A0A151NG86_ALLMI | 3 | 206 |
| C4b-binding protein alpha chain-like | A0A151MAQ5_ALLMI | 5 | 206 |
| Serpin peptidase inhibitor, clade A (Alpha-1 antiproteinase, antitrypsin), member 4 | A0A151P987_ALLMI | 5 | 201 |
| Ovostatin-like protein 1-like | A0A151MRY5_ALLMI | 3 | 198 |
| Adiponectin | A0A151M626_ALLMI | 2 | 181 |
| Ig-like domain-containing protein | A0A151M7S2_ALLMI | 2 | 176 |
| Plasma protease C1 inhibitor | A0A151NVG0_ALLMI | 3 | 173 |
| Uncharacterized protein | A0A151NG84_ALLMI | 3 | 173 |
| Stanniocalcin-2 | A0A151M6X4_ALLMI | 3 | 168 |
| Pantetheinase | A0A151M3D7_ALLMI | 3 | 162 |
| Uncharacterized protein | A0A151MFZ3_ALLMI | 3 | 155 |
| Retinoic acid receptor responder protein 2 | A0A151LYA0_ALLMI | 2 | 161 |
| Protein AMBP | A0A151MF04_ALLMI | 2 | 139 |
| Ig-like domain-containing protein | A0A151P541_ALLMI | 2 | 138 |
| V-set domain-containing T-cell activation inhibitor 1-like | A0A151MVY5_ALLMI | 3 | 137 |
| Protein Z-dependent protease inhibitor | A0A151P8Q1_ALLMI | 3 | 135 |
| Fibrinogen C-terminal domain-containing protein | A0A151MF29_ALLMI | 2 | 134 |
| Ig-like domain-containing protein | A0A151P538_ALLMI | 2 | 133 |
| Vitelline membrane outer layer 1-like protein | A0A151PFR3_ALLMI | 3 | 132 |
| Apolipoprotein A-IV | A0A151LZQ0_ALLMI | 2 | 131 |
| Ig-like domain-containing protein | A0A151NR11_ALLMI | 2 | 131 |
| Keratin, type I cytoskeletal 14 | A0A151PC58_ALLMI | 3 | 130 |
| Vitronectin | A0A151NVP9_ALLMI | 2 | 130 |
| Sushi domain-containing protein | A0A151P1M1_ALLMI | 2 | 129 |
| Uncharacterized protein | A0A151MP64_ALLMI | 3 | 126 |
| Disabled-like protein 1 isoform B | A0A151M4I5_ALLMI | 2 | 121 |
| Beta-2-glycoprotein 1 | A0A151N2D1_ALLMI | 2 | 120 |
| Ig-like domain-containing protein | A0A151M7W3_ALLMI | 1 | 118 |
| Complement component C8 alpha chain | A0A151M4H1_ALLMI | 2 | 113 |
| Histidine-rich glycoprotein | A0A151M7M7_ALLMI | 2 | 112 |
| Chondroadherin isoform A | A0A151N2Q4_ALLMI | 2 | 109 |
| Ig-like domain-containing protein | A0A151M7N2_ALLMI | 1 | 108 |
| Complement factor H-related protein 3-like | A0A151NBK6_ALLMI | 3 | 108 |
| Uncharacterized protein (apolipoprotein E-like) | A0A151N395_ALLMI | 2 | 105 |
| Ig-like domain-containing protein | A0A151P518_ALLMI | 2 | 104 |
| Alpha-1-antitrypsin-like | A0A151P8V8_ALLMI | 2 | 94 |
| Ig heavy chain V region 6.96 | A0A151P441_ALLMI | 2 | 93 |
| Leucine-rich alpha-2-glycoprotein | A0A151MCJ2_ALLMI | 2 | 90 |
| Uncharacterized protein | A0A151MAL5_ALLMI | 2 | 88 |
| Ig-like domain-containing protein | A0A151P518_ALLMI | 2 | 86 |
| Alpha-1-antiproteinase-like | A0A151P8W0_ALLMI | 2 | 82 |
| Insulin-like growth factor-binding protein complex acid labile subunit | A0A151N6V5_ALLMI | 2 | 78 |
| Apolipoprotein B-100 | A0A151PIT1_ALLMI | 3 | 77 |
| Properdin | A0A151MYJ4_ALLMI | 2 | 77 |
| Complement component C7 | A0A151MX90_ALLMI | 2 | 75 |
| Anionic trypsin-2-like | A0A151NL42_ALLMI | 1 | 75 |
| Angiogenin | A0A151MM94_ALLMI | 1 | 73 |
| A0A151PH98_ALLMI | 2 | 72 | |
| Ig-like domain-containing protein | A0A151N4A7_ALLMI | 2 | 72 |
| GRIP and coiled-coil domain-containing protein 2 | A0A151NXH0_ALLMI | 2 | 69 |
| Fibulin-1 | A0A151P794_ALLMI | 2 | 66 |
| Complement C2 | A0A151PIR2_ALLMI | 2 | 63 |
| Selenoprotein P | A0A151MWX0_ALLMI | 2 | 54 |
| Ig-like domain-containing protein | A0A151P973_ALLMI | 1 | 54 |
| Ig-like domain-containing protein | A0A151MRI0_ALLMI | 1 | 53 |
| Pericentrin isoform D | A0A151N9S1_ALLMI | 2 | 53 |
| Uncharacterized protein | A0A151NLI3_ALLMI | 2 | 53 |
| AT-rich interactive domain-containing protein 3B | A0A151MAK9_ALLMI | 2 | 52 |
| Laminin subunit beta-3 isoform A | A0A151MJP2_ALLMI | 2 | 51 |
| Uncharacterized protein | A0A151NFR7_ALLMI | 1 | 51 |
| Signal transducer and activator of transcription | A0A151PC08_ALLMI | 2 | 51 |
| ZZ-type zinc finger-containing protein 3 isoform B | A0A151NJ96_ALLMI | 2 | 50 |
| Ig-like domain-containing protein | A0A151NR16_ALLMI | 1 | 49 |
| WD repeat-containing protein 11 isoform C | A0A151NU67_ALLMI | 2 | 48 |
| Avidin-like | A0A151MRC9_ALLMI | 1 | 47 |
| Complement factor B | A0A151PIT0_ALLMI | 1 | 47 |
| Uncharacterized protein | A0A151MF67_ALLMI | 1 | 46 |
| Complement factor H-like | A0A151NLD7_ALLMI | 1 | 46 |
| Uncharacterized protein | A0A151MT59_ALLMI | 1 | 44 |
| Uncharacterized protein | A0A151NT34_ALLMI | 1 | 44 |
| Sulfhydryl oxidase | A0A151MIB1_ALLMI | 1 | 42 |
| Exostosin-like 1 isoform B | A0A151MMH5_ALLMI | 1 | 42 |
| Putative E3 ubiquitin-protein ligase UBR7 | A0A151P8Y0_ALLMI | 2 | 41 |
| Sorbitol dehydrogenase | A0A151MAA7_ALLMI | 1 | 41 |
| Carboxypeptidase B2 | A0A151MHY8_ALLMI | 1 | 40 |
| T-complex protein 1 subunit eta | A0A151MYL4_ALLMI | 1 | 40 |
| BTB/POZ domain-containing protein 7 | A0A151P8X9_ALLMI | 1 | 39 |
| Citron Rho-interacting kinase isoform B | A0A151N4K3_ALLMI | 1 | 39 |
| Uncharacterized protein | A0A151ND16_ALLMI | 1 | 39 |
| Prickle-like protein 1 isoform A | A0A151PEZ2_ALLMI | 1 | 39 |
| Ras-related protein Rab-17 isoform B | A0A151N9P9_ALLMI | 1 | 38 |
| Uncharacterized protein | A0A151LZX4_ALLMI | 1 | 38 |
| T-lymphoma invasion and metastasis-inducing protein 1 | A0A151ME23_ALLMI | 1 | 38 |
| Uncharacterized protein | A0A151NRI7_ALLMI | 1 | 38 |
| Neuronal PAS domain-containing protein 3 isoform A | A0A151NKE6_ALLMI | 1 | 37 |
| Ankyrin repeat domain-containing protein 26 isoform A | A0A151PEV8_ALLMI | 1 | 37 |
| Cadherin-1 | A0A151P0T5_ALLMI | 1 | 36 |
| Ig-like domain-containing protein | A0A151NR67_ALLMI | 1 | 34 |
| Uncharacterized protein | A0A151M2C1_ALLMI | 1 | 34 |
| Zinc finger castor-like protein 1 isoform C | A0A151N3T3_ALLMI | 1 | 34 |
| Ubiquitin carboxyl-terminal hydrolase 8 isoform C | A0A151M9E3_ALLMI | 1 | 33 |
| Uncharacterized protein | A0A151P059_ALLMI | 1 | 33 |
| Arf-GAP with coiled coil, ANK repeat, and PH domain-containing protein 1 | A0A151N149_ALLMI | 1 | 33 |
| Membrane-bound transcription factor site-1 protease | A0A151MLJ3_ALLMI | 1 | 33 |
| TRAF family member-associated NF-kappa-B activator | A0A151M0A1_ALLMI | 1 | 32 |
| Pyruvate carboxylase, mitochondrial | A0A151PCD5_ALLMI | 1 | 32 |
| Leukocyte receptor cluster member 8 | A0A151N898_ALLMI | 1 | 32 |
Deiminated proteins in alligator plasma were isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS and peak list files submitted to mascot. Alligator mississippiensis species-specific peptide sequence hits are listed (ALLMI), showing number of sequences for protein hits and total score. Blue highlighted rows indicate protein hits identified in whole plasma only (for full details on protein hits see .
Ions score is −10 × Log(P), where P is the probability that the observed match is a random event. Individual ions scores >32 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits.
Deiminated proteins in plasma extracellular vesicles (EVs) of alligator (Alligator mississippiensis), as identified by F95 enrichment.
| Uncharacterized protein (complement C3) | A0A151NL74_ALLMI | 62 | 3,704 |
| Uncharacterized protein | A0A151NFJ9_ALLMI | 43 | 2,719 |
| Serum albumin | A0A151N5S7_ALLMI | 32 | 1,711 |
| Fibrinogen alpha chain | A0A151PBF3_ALLMI | 25 | 1,672 |
| Fibrinogen beta chain | A0A151PC06_ALLMI | 25 | 1,526 |
| Alpha-2-macroglobulin-like | A0A151NFQ0_ALLMI | 23 | 1,486 |
| Uncharacterized protein (venom factor) | A0A151NM44_ALLMI | 25 | 1,411 |
| Fibrinogen gamma chain | A0A151PB79_ALLMI | 22 | 1,305 |
| Uncharacterized protein | A0A151N583_ALLMI | 22 | 1,262 |
| Uncharacterized protein | A0A151MZ64_ALLMI | 20 | 1,221 |
| Kininogen-1 | A0A151M678_ALLMI | 19 | 1,213 |
| Hemopexin | A0A151NGB2_ALLMI | 18 | 1,107 |
| Melanotransferrin | A0A151MJZ7_ALLMI | 15 | 906 |
| Uncharacterized protein | A0A151MYS3_ALLMI | 13 | 856 |
| Complement receptor type 1-like | A0A151MS72_ALLMI | 15 | 838 |
| Uncharacterized protein | A0A151MJS8_ALLMI | 13 | 791 |
| Carbonic anhydrase 6 | A0A151N4K1_ALLMI | 13 | 736 |
| Uncharacterized protein | A0A151NDR9_ALLMI | 13 | 679 |
| Uncharacterized protein | A0A151MYV2_ALLMI | 8 | 656 |
| Uncharacterized protein | A0A151PB91_ALLMI | 8 | 637 |
| Fetuin-B isoform B | A0A151M7P5_ALLMI | 10 | 576 |
| Carbonic anhydrase 6 | A0A151N4K1_ALLMI | 10 | 540 |
| Plasma kallikrein isoform B | A0A151PAG7_ALLMI | 11 | 533 |
| Uncharacterized protein | A0A151P5P7_ALLMI | 10 | 475 |
| CD5 antigen-like | A0A151PHB7_ALLMI | 6 | 469 |
| Keratin, type I cytoskeletal 19 | A0A151PC64_ALLMI | 7 | 445 |
| Keratin, type I cytoskeletal 20 | A0A151PC95_ALLMI | 8 | 425 |
| Uncharacterized protein | A0A151MAL5_ALLMI | 8 | 407 |
| IF rod domain-containing protein | A0A151LYF4_ALLMI | 8 | 391 |
| Ig lambda chain V-1 region | A0A151P8L7_ALLMI | 4 | 347 |
| Complement factor H | A0A151NM72_ALLMI | 5 | 336 |
| Hemoglobin subunit beta | A0A151PG12_ALLMI | 5 | 326 |
| Keratin, type I cytoskeletal 14 | A0A151PC58_ALLMI | 5 | 325 |
| T-cell surface glycoprotein CD8 beta chain | A0A151P975_ALLMI | 3 | 292 |
| Fibrinogen C-terminal domain-containing protein | A0A151MF51_ALLMI | 4 | 285 |
| Complement C5 | A0A151NUM2_ALLMI | 5 | 281 |
| Plasminogen | A0A151M2C0_ALLMI | 4 | 259 |
| Complement C1q subcomponent subunit B | A0A151MZU2_ALLMI | 4 | 253 |
| Complement C1q subcomponent subunit C | A0A151N005_ALLMI | 3 | 251 |
| Uncharacterized protein | A0A151MYZ1_ALLMI | 5 | 248 |
| Uncharacterized protein | A0A151NDR1_ALLMI | 5 | 236 |
| Glutathione peroxidase | A0A151MUD9_ALLMI | 4 | 234 |
| Uncharacterized protein | A0A151MJK7_ALLMI | 4 | 227 |
| IF rod domain-containing protein | A0A151LYE5_ALLMI | 4 | 223 |
| Uncharacterized protein | A0A151MYX2_ALLMI | 3 | 208 |
| Complement C1q subcomponent subunit A | A0A151MZN0_ALLMI | 3 | 192 |
| Hemoglobin subunit alpha-A | A0A151P678_ALLMI | 4 | 181 |
| Alpha-1-inhibitor 3-like | A0A151M7F0_ALLMI | 4 | 180 |
| Uncharacterized protein | A0A151NSW8_ALLMI | 3 | 154 |
| Ig-like domain-containing protein | A0A151P538_ALLMI | 3 | 145 |
| Histone H4 | A0A151NSZ8_ALLMI | 3 | 130 |
| TED_complement domain-containing protein | A0A151N5Z3_ALLMI | 2 | 126 |
| Ig-like domain-containing protein | A0A151P518_ALLMI | 2 | 126 |
| Uncharacterized protein | A0A151MP64_ALLMI | 2 | 120 |
| Antithrombin-III | A0A151MIW1_ALLMI | 2 | 113 |
| Vitronectin | A0A151NVP9_ALLMI | 2 | 108 |
| HATPase_c domain-containing protein | A0A151NIG2_ALLMI | 1 | 107 |
| Desmin | A0A151MQA4_ALLMI | 2 | 104 |
| Ig-like domain-containing protein | A0A151M7S2_ALLMI | 2 | 103 |
| Heterogeneous nuclear ribonucleoproteins A2/B1 | A0A151MQK4_ALLMI | 2 | 100 |
| Ig epsilon chain C region | A0A151MYW1_ALLMI | 2 | 97 |
| Alpha-1-antitrypsin | A0A151P8P3_ALLMI | 2 | 95 |
| Uncharacterized protein | A0A151N405_ALLMI | 3 | 92 |
| A0A151MCB3_ALLMI | 1 | 87 | |
| Uncharacterized protein | A0A151NG84_ALLMI | 2 | 87 |
| Ovostatin-like protein 1-like | A0A151MRY5_ALLMI | 2 | 83 |
| Histone H2A | A0A151LYY4_ALLMI | 2 | 82 |
| Heterogeneous nuclear ribonucleoprotein U | A0A151MHH8_ALLMI | 1 | 80 |
| Tubulin beta chain | A0A151MZH9_ALLMI | 2 | 78 |
| Heparin cofactor 2 isoform B | A0A151MLS1_ALLMI | 2 | 77 |
| Olfactory receptor | A0A151M3L3_ALLMI | 1 | 73 |
| Anionic trypsin-2-like | A0A151NL42_ALLMI | 1 | 72 |
| Glyceraldehyde-3-phosphate dehydrogenase | A0A151M7G4_ALLMI | 2 | 67 |
| Ovoinhibitor | A0A151MEG6_ALLMI | 2 | 67 |
| Glyceraldehyde-3-phosphate dehydrogenase | A0A151MCM1_ALLMI | 2 | 66 |
| Plasma protease C1 inhibitor | A0A151NVG0_ALLMI | 2 | 63 |
| 40S ribosomal protein SA | A0A151P2K0_ALLMI | 1 | 61 |
| Triosephosphate isomerase | A0A151MCS3_ALLMI | 2 | 60 |
| Heat-shock protein, mitochondrial | A0A151NA12_ALLMI | 1 | 59 |
| Uncharacterized protein | A0A151PC76_ALLMI | 2 | 59 |
| Actin filament-associated protein 1-like 2 isoform D | A0A151NUD0_ALLMI | 2 | 59 |
| Tr-type G domain-containing protein | A0A151MMV6_ALLMI | 1 | 59 |
| Desmoplakin | A0A151ND53_ALLMI | 2 | 58 |
| Uncharacterized protein | A0A151NLW7_ALLMI | 2 | 57 |
| Ig-like domain-containing protein | A0A151MRI0_ALLMI | 1 | 55 |
| Tubulin alpha chain | A0A151N6Z6_ALLMI | 1 | 53 |
| Fibrinogen C-terminal domain-containing protein | A0A151MF29_ALLMI | 1 | 53 |
| Serpin peptidase inhibitor, clade A (Alpha-1 antiproteinase, antitrypsin), member 4 | A0A151P987_ALLMI | 1 | 51 |
| Vitamin D-binding protein | A0A151N541_ALLMI | 2 | 50 |
| 60S ribosomal protein L23a | A0A151MUP1_ALLMI | 1 | 47 |
| Tropomyosin alpha-1 chain isoform | A0A151MA07_ALLMI | 1 | 46 |
| Kinesin motor domain-containing protein | A0A151M9A9_ALLMI | 2 | 46 |
| Selenoprotein P | A0A151MWX0_ALLMI | 1 | 45 |
| Golgin subfamily A member 3 isoform A | A0A151NRP7_ALLMI | 2 | 43 |
| Serine incorporator 4 | A0A151M668_ALLMI | 1 | 42 |
| Cleavage and polyadenylation specificity factor subunit 6 isoform B | A0A151PFC7_ALLMI | 1 | 42 |
| Protein AHNAK2 | A0A151MYU6_ALLMI | 1 | 41 |
| Uncharacterized protein | A0A151M202_ALLMI | 1 | 40 |
| BTB/POZ domain-containing protein 7 | A0A151P8X9_ALLMI | 1 | 40 |
| IgGFc-binding protein-like | A0A151MJC3_ALLMI | 1 | 40 |
| 60S ribosomal protein L11 isoform A | A0A151MML3_ALLMI | 1 | 40 |
| Steroid 17-alpha-hydroxylase/17,20 lyase | A0A151NV24_ALLMI | 2 | 39 |
| Small G protein signaling modulator 1 isoform B | A0A151NSF2_ALLMI | 1 | 39 |
| Ig-like domain-containing protein | A0A151N4A7_ALLMI | 1 | 39 |
| TRAF family member-associated NF-kappa-B activator | A0A151M0A1_ALLMI | 1 | 38 |
| 40S ribosomal protein S26 | A0A151NSA5_ALLMI | 1 | 38 |
| Coagulation factor XII | A0A151NM16_ALLMI | 1 | 38 |
| Sushi domain-containing protein | A0A151NM16_ALLMI | 1 | 37 |
| Complement factor H-related protein 3-like | A0A151NBK6_ALLMI | 1 | 36 |
| Cadherin-1 | A0A151P0T5_ALLMI | 1 | 36 |
| Histidine-rich glycoprotein | A0A151M7M7_ALLMI | 1 | 34 |
| TED_complement domain-containing protein | A0A151M7E8_ALLMI | 1 | 34 |
| Zinc finger castor-like protein 1 isoform C | A0A151N3T3_ALLMI | 1 | 34 |
| V-set domain-containing T-cell activation inhibitor 1-like | A0A151MVY5_ALLMI | 1 | 34 |
| C4b-binding protein alpha chain-like | A0A151MAQ5_ALLMI | 1 | 33 |
| Neuronal PAS domain-containing protein 3 isoform A | A0A151NKE6_ALLMI | 1 | 33 |
| Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 | A0A151N149_ALLMI | 1 | 33 |
| Tubulin alpha-2 chain | A0A151LY82_ALLMI | 1 | 32 |
Deiminated proteins from EVs were isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched eluate was then analyzed by LC-MS/MS and peak list files submitted to mascot. Alligator mississippiensis species-specific peptide sequence hits are listed (ALLMI), showing the number of sequences for protein hits and total score. Rows highlighted in pink indicate protein hits identified in plasma EVs only (for full details on protein hits, see .
Ions score is −10 × Log(P), where P is the probability that the observed match is a random event. Individual ions scores >32 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits.
Figure 3Deiminated proteins identified in alligator plasma and plasma extracellular vesicles (EVs). Species-specific hits identified for deiminated proteins in American alligator plasma and EVs showed overall 145 proteins identified in plasma and 100 in EVs. Of these, 69 protein hits were overlapping, while 76 proteins were specific for whole plasma and 31 for plasma EVs only, respectively.
Figure 4Protein–protein interaction networks of all deiminated proteins identified in alligator plasma. Reconstruction of protein–protein interactions based on known and predicted interactions in Alligator mississippiensis, using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis. (A) Colored nodes represent query proteins and first shell of interactors. (B) Protein families (PFAM) protein domains relating to the identified proteins and reported in STRING are highlighted for: serpin, alpha-2-macroglobulin family, sushi repeat, anaphylatoxin-like domain, trypsin, serum albumin family, C1q domain, low-density lipoprotein (LDL)-receptor domain class A, membrane attack complex (MAC)/perforin domain, and hemopexin (see color code included in the figure). (C) Simple Modular Architecture Research Tool (SMART) protein domains relating to the identified proteins and reported in STRING are highlighted for serine proteinase inhibitors, domain abundant in complement control proteins, anaphylatoxin homologous domain, trypsin-like serine protease, serum albumin, MAC/perforin, Ig V-type, hemopexin-like repeats, von Willebrand factor (vWF) type A domain, and leucine-rich repeat C-terminal domain (see color code included in the figure). (D) UniProt keywords relating to the identified proteins and reported in STRING are highlighted for: signal, disulfide bond, sushi, secreted, serine protease, collagen, kringle, hydrolase, and protease (see color code included in the figure). (E) KEGG pathways relating to the identified proteins and reported in STRING are highlighted as follows: red = ECM-receptor interaction. Colored lines indicate whether protein interactions are identified via known interactions (curated databases, experimentally determined), predicted interactions (gene neighborhood, gene fusion, gene co-occurrence), or via text mining, coexpression, or protein homology (see the color key for connective lines included in the figure).
Figure 7Protein–protein interaction networks of deiminated protein candidates identified in alligator extracellular vesicles (EVs) only (not identified in total plasma). Reconstruction of protein–protein interactions based on known and predicted interactions using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis. (A) Colored nodes represent query proteins and first shell of interactors. (B) Protein families (PFAM) protein domains relating to the identified proteins and reported in STRING are highlighted as follows: intermediate filament protein, TILa domain, keratin type II head, C8 domain, trypsin inhibitor-like cysteine-rich domain, von Willebrand factor (vWF) type D domain, core histones H2A/H2B/H3/H4 (see color code included in the figure). (C) Simple Modular Architecture Research Tool (SMART) protein domains relating to the identified proteins and reported in STRING are highlighted as follows: intermediate filament protein, conserved cysteine residues, vWF type D domain, and vWF type C domain (see color code included in the figure). (D) UniProt keywords relating to the identified proteins and reported in STRING are highlighted as follows: ribonucleoprotein, intermediate filament, nucleosome core, ribosomal protein, glycolysis, and viral nucleoprotein (see color code in legend). (E) INTERPRO protein domains and features: intermediate filament protein conserved site, histone H4, TILa domain, keratin type II, trypsin inhibitor-like cysteine-rich domain, serine protease inhibitor-like superfamily, vWF type D domain, histone H2A/H2B/H3, von Willebrand factor type C (VWFC) domain (see color code included in the figure). (F) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relating to the identified deiminated proteins and reported in STRING are highlighted as follows: ribosome, biosynthesis of amino acids, and glycolysis/gluconeogenesis.
Figure 5Protein–protein interaction networks of all deiminated proteins identified in plasma extracellular vesicles (EVs) of Alligator mississippiensis. Reconstruction of protein–protein interactions based on known and predicted interactions using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis. (A) Colored nodes represent query proteins and first shell of interactors. (B) Protein families (PFAM) protein domains relating to the identified proteins and reported in STRING are highlighted as follows: alpha-2-macroglobulin family, intermediate filament protein, fibrinogen chain family, anaphylatoxin-like domain, serum albumin family, serpin, C1q domain, sushi repeat, hemopexin, and core histones (see color code included in the figure). (C) SMART protein domains relating to the identified proteins and reported in STRING are highlighted as follows: domain abundant in complement control proteins, anaphylatoxin homologous domain, serine proteinase inhibitors, trypsin-like serine protease, intermediate filament protein, fibrinogen-related domains, hemopexin-like repeats, C1q domain, alpha-2-macroblobulin family, and serum albumin (see color code included in the figure). (D) UniProt keywords relating to the identified proteins and reported in STRING are highlighted as follows: intermediate filament, signal, secreted, disulfide bond, ribonucleoprotein, sushi, glycolysis, serine protease, nucleosome core, ribosomal protein (see color code included in the figure). (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relating to the identified proteins and reported in STRING are highlighted as follows: red = ribosome. Colored lines indicate whether protein interactions are identified via known interactions (curated databases, experimentally determined), predicted interactions (gene neighborhood, gene fusion, gene co-occurrence), or via text mining, coexpression, or protein homology (see the color key for connective lines included in the figure).
Figure 6Protein–protein interaction networks of deiminated protein candidates identified in alligator plasma only (not identified in extracellular vesicles (EVs). Reconstruction of protein–protein interactions based on known and predicted interactions using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis. (A) Colored nodes represent query proteins and first shell of interactors. (B) Protein families (PFAM) protein domains relating to the identified proteins and reported in STRING are highlighted as follows: sushi repeat, serpin, low-density lipoprotein (LDL)-receptor domain class A, von Willebrand factor (vWF) type A domain, membrane attack complex (MAC)/perforin domain, thrombospondin type 1 domain, leucine-rich repeat N-terminal domain, and trypsin (see color code included in the figure). (C) Simple Modular Architecture Research Tool (SMART) protein domains relating to the identified proteins and reported in STRING are highlighted as follows: domain abundant in complement control proteins, serine proteinase inhibitors, anaphylatoxin homologous domain, LDL-receptor domain class A, MAC/perforin, thrombospondin type 1 repeats, vWF type A domain, leucine-rich repeat C-terminal domain, trypsin-like serine protease, leucine-rich repeats (see color code included in the figure). (D) UniProt keywords relating to the identified proteins and reported in STRING are highlighted as follows: sushi, signal, disulfide bond, protease, leucine-rich repeat (see color code included in the figure). (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relating to the identified proteins and reported in STRING are highlighted as follows: red = adipocytokine signaling pathway.
Figure 8Sequence alignment and phylogeny tree for alligator peptidylarginine deiminases (PADs) compared with human PADs. (A) Multiple sequence alignment of reported (predicted) alligator PAD sequences PAD1 (XP_006259278.3), PAD2 (XP_019355592.1), and PAD3 (XP_014457295.1) isozymes, compared with human PAD isozyme protein sequences PAD1 (NP_037490.2), PAD2 (NP_031391.2), PAD3 (NP_057317.2), PAD4 (NP_036519.2), and PAD6 (NP_997304.3), using Clustal Omega. (B) A neighbor joining tree is shown for phylogenetic clustering of the reported (predicted) alligator PAD1 (XP_006259278.3), PAD2 (XP_019355592.1), and PAD3 (XP_014457295.1) isozymes, compared with human PAD isozyme protein sequences PAD1 (NP_037490.2), PAD2 (NP_031391.2), PAD3 (NP_057317.2), PAD4 (NP_036519.2), and PAD6 (NP_997304.3), using Clustal Omega.